Asgard Therapeutics
PrivateLast Round
Grant
Mar 11, 2025
Total Funding Raised
$39.85M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Asgard Therapeutics is a biotechnology company that develops innovative gene therapy products leveraging direct cell reprogramming for personalized cancer immunotherapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asgard Therapeutics Comparables
Compare Asgard Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Reprogram Biosciences | 83% | |
| Lokon Pharma | 78% | |
| Qurgen | 78% | |
Asgard Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 11, 2025 | ||||
| Series A | Mar 14, 2024 | ||||
| Seed | Nov 9, 2021 | ||||
| Grant | Apr 6, 2020 |
Asgard Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Boehringer Ingelheim | Series A, Seed |
| Vinnova | Grant |
| Industrifonden | Series A, Seed |
| Novo Holdings | Series A, Seed |
| RV Invest | Series A |
| Boehringer Ingelheim Venture Fund | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Oral presentation at ASGCT 2026 showcasing cancer immunotherapy data.
- Apr 27, 2026
Oral presentation at ASGCT 2026 on preclinical data for AT-108.
Asgard Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Asgard Therapeutics's valuation, stock price, and market status.